surface receptors to the interior of the cell, and thereby regulates a wide variety of cell functions.T he binding of extracellular factors, inflammatory mediators, and growth factors to their specific cell surface receptors results in receptor activation and, in many instances, activation of phospholipase C (PLC).P LC catalyses hydrolysis of membrane-associated inositol-containing phosphollpids (phosphatidylinositol) 1995 Briti.sh Association of Dermatologists to yield at least two important second messengers, inositol trisphosphate. which mobilizes calcium from intracellular stores, and 1.2-diacylglycerol (1.2-DAG), the physiological activator of PKC. Ligand-cell surface receptor interaction may also result in hydrolysis of choline-containing phospholipids (phosphatidylcholine). through the action of phosphatidylcholinespecific PLC or phospholipase D. and lead to the formation of 1.2-DAG and activation of PKC.^'T umour-promoting phorbol esters, for example 12-0-tetradecanoylphorbol-13-acetate (TPA), directly bind to and activate PKC.
PKC comprises a family of isoenzymes, encoded by at least nine genes, which display selective organ and cellular expression.^'^''*"^ and exhibit functional diversity/'^'^'^*' suggesting that different isoenzymes may have different physiological roles. PKC isoenzymes are classified into calcium-dependent (PKC-a l3l, BII and 7), calcium-independent (PKC-6. e, TJ (L). and 9). and atypical [C and / (A)] forms.^-^ PKC-a. 01. ,511. S, e, C and T) have been detected in human skin.'^'^ It is of interest that PKC-/3 appears to be abundantly expressed hy epidermal Langerhans cells (LC).''"'^" Purthermore. application of TPA or synthetic diglyceride to mouse and human skin results in downregulation of Ca'"-dependent PKC activity/^ a reduction of epidermal LCs, and suppression of allergic contact dermatitis.^ P KC activation is associated with rapid translocation of the enzyme from the cytosol to the membrane, and this is followed by proteolysis. ' Thus. prolonged activation of PKC results in its down-regulation. However. PKC isoenzymes vary in their susceptibility to translocation and down-regulation, possibly due to differences in subcellular localization and requirements for different co-factors, and this appears to be cell type-dependent.**'^' PKC regulates epidermal growth, differentiation, expression of adhesion molecules and leucocyte trafficking.^'^^'^ Recent studies indicate that there are significant abnormalities of PKC signalling in psoriasis: (i) both soluble and membrane-bound PLC activities are significantly elevated in lesional psoriatic epidermis compared with non-lesional and normal epidermis; [21] [22] [23] (ii) 1.2-DAG mass is significantly higher in psoriatic lesional skin compared with normal skin:"" (iii) PKC activity is significantly decreased in both lesional and non-lesional psoriatic epidermis compared with normal skin;^^^"" (iv) PKCa and PKC-/? protein levels are reduced in psoriatic epidermis compared with normal, as assessed by Western analysis and immunohistochemistry/ However, whether these changes are specific for psoriasis is currently unknown. To address this question, we have used immunohistochemical techniques to examine the expression of PKC-a and PKC-/3 isoenzymes and the concurrence of PKC-/3 and CD la in LCs, in a variety of infiammatory and hyperplastic dermatoses.
Methods

Patients
Pifteen adult volunteers {10 males, five females: mean age 38 years, range 20-55), who were otherwise in good health and taking no medication, were recruited for study. Seven of the volunteers (six male, one female: mean age 35 years, range 20-55 years} gave a history of poison ivy dermatitis. Patients with clinical and histological features of lamellar ichythosis (three female: mean age 38 years, range 24-47). non-buUous ichthyosiform erythroderma (three male; mean age 24 years, range [23] [24] [25] [26] [27] . atopic dermatitis (two male, three female: mean age 36 years, range 21-56), cutaneous T-cell lymphoma (CTCL, four male, two female: mean age 51 years, range 37-81), and psoriasis (five male, two female: mean age 44 years, range 30-57), were also selected for study. The study was approved by the University of Michigan Medical Center institutional review board, and all patients gave written informed consent to participation.
Induction of irritant and allergic contact dermatitis
Por induction of allergic contact dermatitis, urushiol was applied to the seven volunteers who gave a history of poison ivy dermatitis.^^ Twenty microUtres of urushiol (poison ivy/oak mixture, Hollister-Stier, Elkhart, IN, U.S.A.), 1:50 in ethanol, was applied under occlusion, using the Altest System (Sodertalje. Sweden), to four different sites (5 mm diameter. 5 cm apart) on the buttock. Evaluations and punch biopsies were performed at 0, 1, 8, 24 and 48 h after application.
For induction of irritant contact dermatitis, sodium lauryl sulphate (SLS, 2% in Retin A-vehicle, Ortho Pharmaceutical. Raritan. NJ. U.S.A.) and vehicle were applied under occlusion to the buttocks of eight volunteers, as previously described. ' and punch biopsies were performed 4 days later. 
Biopsy procedure
Eour-mm punch biopsies, obtained under local anaesthesia, were embedded in optimal cutting temperature (OCT) compound (Miles Lahoratories. Elkhart. IN. U.S.A.), frozen in isopentane, precooled hy liquid nitrogen, and stored at -7O''C until analysis.
Immunohistochemistry
Eive-micron sections were cut on a cryostat. and stained with monoclonal antibodies to PKC-a. PKC-/3 (Seikagaku, Rockville, MD. U.S.A.), or CDla, a LC marker, (Becton Dickinson. Burlingame, CA, U.S.A.). PKC-a and PKC-/3 antibodies have previously been characterized.^'*'^" and shown to detect appropriate molecular weight proteins in skin by Western analysis.' Substitution of the primary antibody with isotype-specific IgG, and omission of the primary antibody, served as negative controls. When using single antibodies, sections were developed using an avidin-biotin immunoperoxidase technique (Vectastain ABC. Vector Laboratories. Burlingame. CA. U.S.A.). with 3-amino 9-ethylcarbazole (AEC) as the chromogen. and counterstained with 1% haematoxylin. Eor double-staining, the first antibody was visualized using an avidin-biotin immunoperoxidase technique, with 3.3'-diaminobenzidine (DAB) as the chromogen. and the second antibody visualized using an alkaline phosphatase/anti-alkaline phosphatase technique, with fast blue as the chromogen, as described previously.*'
Assessment of staining
The numbers of PKC-/3+ and CDla^ epidermal LCs in four high-power fields (objective x40) were counted by a single observer. The staining intensity of PKC-0'^ epidermal LCs. and the degree of PKC-/3 staining in the dermis. were evaluated by two observers using an ordinal 0-4 scale, where 0 = no staining; 1 = minimal: 2 = minimal-moderate: 3 = moderate: and 4 -maximal staining.
Statistical analysis
the The two-sample (-test was used to compare number and staining intensity of PKC-/?^ and cells in the epidermis and dermis of normal volunteers vs. patients with the aforementioned dermatoses. Comparisons of PKC-,5"^/CDla^ ratio among the dermatoses studied were performed by the analysis of variance method and the least-significance-test. The paired t-test was used to compare sites of experimentally induced irritant or allergic contact dermatitis with the control site in the same individual. All Pvalues are two-sided. Summary statistics are represented as means ± SEM. The data were analysed with the Michigan Interactive Data Analysis System, a statistical software package developed by the Center for Statistical Consultation and Research at the University of Michigan.
Results
Co-localization ofPKC-/3 and CDla in human Langerhans cells
In normal skin, immunostaining with PKC-/? revealed strong expression in epidermal and dermal dendritic cells, and weak keratinocyte staining ( Fig. 1) , as previously reported/ Double-labelling showed co-localization of PKC-/3 and CDla in epidermal dendritic cells, confirming that these cells were LCs (Eig. 1).
Expression of PKC-a and PKC-p isoemymes in inflammatory and hyperplastic dermatoses
'Q expression. Immunostaining with PKC-a revealed weak keratinocyte and dermal expression, which was unaltered in the diseases studied (data not shown).
expression. Compared with PKC-/3 immunostaining observed in normal skin, significant alterations of epidermal and/or dermal PKC-/? expression were observed in all of the disease states studied, except for non-lesional psoriatic skin (Eigs 2-4).
Analysis of the number of PKC-/3^ and epidermal LCs in the dermatoses studied, compared with normal skin, revealed three categories (Eig. 3 and Table 1 ). (i) The number of PKC-/3+ LCs/h.p.f. was significantly lower in lesional psoriatic skin and CTCL, than in normal skin (P < 0-005), whereas the number of CDla^ epidermal LCs/h.p.f. was not significantly different (Eigs 2 and 3). Consistent with this, the ratio of PKC-/?^/CDla+ epidermal LCs was 0-33 ±0-05 in lesional psoriatic skin and 051 ±0-1 in CTCL, compared with 0-82 ±0 03 in normal skin (P < 0-005).
(ii) The number of ?KC-0^ and CDla+ epidermal LCs/h.p.f. was reduced in urushiol-induced allergic contact dermatitis at 24 h, and SLS-induced Irritant CTCL Lesional Nonn = 7 contact contact n = 6 psoriasis iesional dermatitis dermatitis n = 7 psoriasis (urushiol) (SLSI) n = 7 n=7 n=7
Atopic dermatitis irritant contact dermatitis, compared with normal skin, or vehicle in the case of SLS-induced irritant contact dermatitis (P < 0-05: Figs 2 and 3) . The reduction of PKC-/r epidermal LCs could be due. in part, to movement of PKC-/3^/CDla+ LCs out of the epidermis. However, the ratio of PKC-/3^/CDla"^ epidermal LCs was significantly reduced in SLS-treated skin (0-53 ±007) compared with vehicle (0-73 ±0 03; P < 0-05). and showed a trend towards reduction in urushiol-treated skin (0-68 ±0-03) compared with 0-82 ± 0 03 in normal skin {P = 0-06). These data suggest that reduction of PKC-^^ epidermal LCs could not be fully accounted for by migration of PKC-/?^/CDla^ LCs out of the epidermis, and that LC PKC-/3 was activated and then down-regulated during urushiol-induced allergic con- tact dermatitis and SLS-induced irritant contact dermatitis, (iii) The number of CDla^ epidermal LCs/ h.p.f. was significantly increased in atopic dermatitis, compared with normal skin (P< 0-0001). as previously reported.*" There was. however, no corresponding increase in the number of PKC-/3^ epidermal LCs, compared with normal skin, and indeed the intensity of PKC-/5 epidermal LC staining was reduced (1-6 ±0 1) compared with normal skin (24 ±01; P < 0 005). Moreover, the ratio of PKC-/3+/CDla"^ epidermal LCs was significantly decreased in atopic dermatitis (0-5± 005) compared with normal skin (0 82 ±0 03: P < 0-001). suggesting modulation of epidermal LC PKC-/^ in atopic dermatitis. In order to examine the effects of epidermal hyperplasia in isolation, i.e. in the absence of inflammation, on PKC-0 immunostaining. we investigated patients with lamellar ichthyosis and non-bullous ichthyosiform erythroderma. We observed significantly reduced numbers of PKC-/3^ epidermal LCs/ h.p.f. in lamellar ichthyosis (5-8 ± 11) and non-bullous ichthyosiform erythroderma (54 ±1-8). compared with normal skin (12-2 ±0-4; P < 0-005). A trend towards a reduction of CDla^ epidermal LC number was also observed (P = 006) in lamellar ichthyosis. but not in non-bullous ichthyosiform erythroderma. In addition, the ratio of PKC-/3+/CDlaê pidermal LCs was significantly reduced in lamellar ichthyosis (0-53 ±0 01) and non-bullous ichthyosiform erythroderma (0-40 ± 01), compared with normal skin (0-82 ± 0 03: P < 0-005). These data suggest that modulation of epidermal LC PKC-/? expression may occur in the absence of significant inflammatory change. In the dermis. significantly increased staining with PKC-/?, predominantly in dendritic cells, was observed in all of the dermatoses studied (P < 005). except for lamellar ichthyosis and non-bullous ichthyosiform erythroderma (data not shown). Increased dermal staining with CDla was observed in CTCL. atopic dermatitis, allergic and irritant contact dermatitis, but not psoriasis, lamellar ichthyosis, or non-bullous ichthyosiform erythroderma (data not shown}.
Vrushiol-induced allergic contact dermatitis
We performed a detailed time-course analysis of PKC-0 and CDla expression following the topical application of urushiol to previously sensitized subjects. PKC-/3^ epidermal LC number was significantly reduced, compared with normal skin, at 1 h, and this was accompanied by a reduction in CDla* epidermal LCs (Fig. 4) . The numbers of PKC-d^ and CDlaê pidermal LCs remained lower than in normal skin for the duration of this study (up to 48 h) (Fig. 4) . It is of interest that no increase in PKC-f3 or CDla dermal staining was observed until 24 h (data not shown), suggesting that the increase in this population of cells is not related to early migration of PKC-/3^ and CDla^ epidermal LCs to the dermis.
Discussion
In psoriatic lesional skin. Ca^^-dependent PKC activity, PKC-Q and -0 protein levels, and epidermal LC PKC-^ immunostaining are significantly decreased, indicating previous activation of PKC-a and -3. with subsequent down-regulation.' In the present study.
we investigated whether these changes are specific for psoriasis, by examining PKC-a and PKC-/3 expression in normal skin and a variety of inflammatory and hyperpiastic skin diseases. We have extended our previous observations in normal skin'^ to clearly demonstrate co-expression of PKC-/3 and CDla by epidermal LCs. Furthermore, we have demonstrated that modulation of epidermal and dermal LC PKC-3 expression occurs in a number of inflammatory and hyperpiastic skin diseases, with distinct underlying pathogenic mechanisms.
The distinct patterns of distribution of PKC isoenzymes among tissues suggests isoenzyme functional specificity.^''^ The intensity of PKC-/3 immunostaining by LCs observed in the present and previous studies.''"^ ^"^^ suggests abundant LC PKC-/? expression. This is further supported by the observation that removal of CDla^ LCs from epidermal cell suspensions, using immunomagnetic beads, results in a significant reduction of Ca^^-dependent PKC activity and PKC-/3 protein. Recent evidence suggests that activation of PKC induces migration of LCs from mouse epidermis.^^ and that TPA treatment of murine epidermis prior to sensitization inhibits contact hypersensitivity.'* Furthermore, PKC is involved in macrophage activation required for interaction with T cells,^^ and PKC may also be activated through HLA-DR class II molecules.^* Thus, it is possible that PKC may play a fundamental part in LC function and antigen presentation.
There is clearly a complex relationship between PKC-/3 and CDla expression by LCs in both the epidermis and dermis (Fig. 3 and Table 1 ). A reduction of PKC-/3^ epidermal LCs without a reduction in CDla"^ epidermal LCs in CTCL, as well as in psoriasis ( Fig. 3 and Table 1 ), indicates that activation and down-regulation of LC PKC-,5 is not unique to psoriasis.
One possible explanation for the reduction in PKC-0'^ epidermal LCs in urushiol-induced allergic contact dermatitis and SLS-induced irritant cotitact dermatitis is movement of PKC-/3+ CDla+ LCs out of the epidermis, as CDla^ epidermal LCs were also decreased in number ( Fig. 3 and Table 1 ). On the other hand, the apparent reduction in the number of CDla"^ epidermal LCs may reflect depletion of epidermal LC surface CD la. with retention of normal numbers of LCs within the epidermis, as has been observed following exposure of human skin to UVB or PUVA.^''^^ However, previous studies have shown reduction of ATPase^ epidermal LCs during the early afferent phase (4-24 h) of allergic contact dermatitis in mouse and human skin,''^'^** and accumulatioti of epidermal LCs in draining lymph nodes has been reported after application of contact allergens. The role of LCs In Irritant contact dermatitis is less well deflned. but a reduced CDla"^ epidermal LC number, and increased CDla^ LCs in afferent lymph, have been reported following exposure to SLS.^^"*"'*^ It is of interest that recent studies have indicated that movement of epidermal LCs out of the epidermis is mediated by activation of PKC.^^ The reduced ratio of ?KC-P'/CDla^ epidermal LCs in urushtol-induced allergic contact dermatitis, and SLS-induced irritant contact dermatitis, compared with normal skin (Fig.  3 and Table 1 ). indicates modulation of epidermal LC PKC-i3~^. and suggests activation and subsequent down-regulation of PKC-/3. The application of urushiol to sensitized subjects resulted in a reduction in the number of PKC-0^ and CDla"*^ epidermal LCs u^ithin 1 h (Fig. 4) . during the pre-erythematous phase, and prior to lymphocyte entry.^^ We therefore suggest that activation of PKC-/3 may transduce the signal which initiates LC migration out of human epidermis. Thus, activation of epidermal LC PKC-^ may play an important part in the early phase of allergic and irritant contact dermatitis. Urushiol is a weak PKC agonist and may. therefore, directly activate LC PKC.*â lthough the signal resulting in activation of PKC-/? may relate to antigen processing or release of keratinocyte-derived cytokines.*^ SLS-induced activation and down-regulation of epidermal LC PKC-/3 may account, in part, for decreased Ca~^-dependent PKC activity in SLS-treated epidermis.'*'* In atopic dermatitis, we confirmed an increase in CDla* epidermal LCs compared with normal skin^ (  Fig. 3 and Table 1 ). Modulation of epidermal LC PKC-/? in atopic dermatitis, indicated by a reduced ratio of PKC-/?^/CDla^ epidermal LCs, suggests that PKC-/3 may be involved with other LC functions, in addition to migration.
Although hyperplasia and active inflammation were observed in the majority of disease states studied, reduced epidermal LC PKC-/? expression was observed in the absence of a signiflcant inflammatory infiltrate in lamellar ichthyosis and non-bullous ichthyosiform erythroderma. suggesting the possibility of keratinocyte-LC interaction. Also, reduction of epidermal LC PKC-^ occurred during the very early stages of urushiol-induced allergic contact dermatitis, prior to lymphocyte entry. This suggests that direct effects of urushiol'*^ or, more probably, keratinocytederived cytokines. may account for activation and down-regulation of epidermal LC PKC-/?.
In conclusion, modulation of LC PKC-0 is not unique to psoriasis, and occurs In other skin diseases. Indeed, we observed down-regulation of LC PKC-/? in all of the inflammatory and hyperplastic skin diseases which we studied. Although this may suggest that modulation of PKC-,5 is a non-specific event, distinct patterns of PKC-/? and CDla alterations were observed among the diseases studied. In particular, down-regulation of PKC-/? was associated with reduced CDlaê pidermal LCs in allergic and irritant contact dermatitis. In mice and humans, activation qf PKC has been implicated in migration of LCs out of the epidermis,'^'^^ and our data therefore suggest that activation of epidermal LC PKC-/? may be involved in initiating outward migration of LC in aflergic and irritant contact dermatitis. Whether modulation of epidermal LC PKC-/? observed in other inflammatory and hyperplastic diseases is concerned with altered migration of epidermal IXs requires further study, but PKC-/? may also be involved in other LC functions, for example LC-T-ceil interactions.^^'^^ In the present study, we investigated skin diseases characterized by epidermal hyperplasia and inflammation, because PKC is known to regulate these processes. Whether epidermal LC PKC-/? is modulated in skin diseases with different pathogenic mechanisms requires further study.
